Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 2/20 | 0.48 |
| ▸ | FYN | P06241 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | NR2F2 | P24468 | 4/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21524286 | 0.86 | ALDH1A1 (0.46) | CRBNALDH1A1L3MBTL1HCAR2LMNA | |
| SCHEMBL27590640 | 0.85 | ALDH1A1 (0.53) | CRBNALDH1A1L3MBTL1HCAR2LMNA | |
| SCHEMBL27644553 | 0.83 | ALDH1A1 (0.56) | CRBNALDH1A1L3MBTL1HCAR2LMNA | |
| SCHEMBL27624273 | 0.83 | ALDH1A1 (0.56) | CRBNALDH1A1L3MBTL1HCAR2LMNA | |
| SCHEMBL27643721 | 0.83 | ALDH1A1 (0.56) | CRBNALDH1A1L3MBTL1HCAR2LMNA | |
| SCHEMBL27624276 | 0.83 | ALDH1A1 (0.56) | CRBNALDH1A1L3MBTL1HCAR2LMNA | |
| SCHEMBL19438354 | 0.80 | CRBN (0.52) | CRBNALDH1A1L3MBTL1LMNACYP2C19 | |
| SCHEMBL1777117 | 0.77 | — | — | |
| SCHEMBL1777044 | 0.77 | — | — | |
| SCHEMBL1202062 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3812371-A1 | A PROCESS FOR PREPARING BRIVARACETAM | Divi's Laboratories Limited (IN) | 2021-04-28 | — | — | EP | claimed |
| US-10781170-B1 | Process for preparing Brivaracetam | DIVI'S LABORATORIES LTD. (IN) | 2020-09-22 | — | — | US | claimed |
| CN-121270460-A | Preparation method of 4-propyl-2, 6-piperidinedione compound | 浙江华海药业股份有限公司 | 2026-01-06 | — | — | CN | disclosed |
| CN-121270460-A | Preparation method of 4-propyl-2, 6-piperidinedione compound | 浙江华海药业股份有限公司 | 2026-01-06 | — | — | CN | disclosed |
| CN-118028391-A | Preparation method of S-configuration monoamide compound and brivaracetam intermediate | 北京泛球生物科技有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-112739683-B | Preparation method of brivaracetam and intermediate thereof | 上海宣泰医药科技股份有限公司 | 2024-04-16 | — | — | CN | disclosed |
| US-11884623-B2 | Process for the preparation of (R)-4-propyl pyrrolidine-2-one, a key intermediate for synthesis of brivaracetam | DIVI'S LABORATORIES LTD. (IN) | 2024-01-30 | — | — | US | disclosed |
| EP-4282971-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF (R )-4-PROPYL PYRROLIDINE-2-ONE, A KEY INTERMEDIATE FOR SYNTHESIS OF BRIVARACETAM | Divi's Laboratories Limited (IN) | 2023-11-29 | — | — | EP | disclosed |
| EP-4282971-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF (R )-4-PROPYL PYRROLIDINE-2-ONE, A KEY INTERMEDIATE FOR SYNTHESIS OF BRIVARACETAM | Divi's Laboratories Limited (IN) | 2023-11-29 | — | — | EP | disclosed |
| US-20230373914-A1 | PROCESS FOR THE PREPARATION OF (R)-4-PROPYL PYRROLIDINE-2-ONE, A KEY INTERMEDIATE FOR SYNTHESIS OF BRIVARACETAM | DIVI'S LABORATORIES LTD. (IN) | 2023-11-23 | — | — | US | disclosed |
| US-20230373914-A1 | PROCESS FOR THE PREPARATION OF (R)-4-PROPYL PYRROLIDINE-2-ONE, A KEY INTERMEDIATE FOR SYNTHESIS OF BRIVARACETAM | DIVI'S LABORATORIES LTD. (IN) | 2023-11-23 | — | — | US | disclosed |
| US-20230373914-A1 | PROCESS FOR THE PREPARATION OF (R)-4-PROPYL PYRROLIDINE-2-ONE, A KEY INTERMEDIATE FOR SYNTHESIS OF BRIVARACETAM | DIVI'S LABORATORIES LTD. (IN) | 2023-11-23 | — | — | US | disclosed |
| EP-3812371-A1 | A PROCESS FOR PREPARING BRIVARACETAM | Divi's Laboratories Limited (IN) | 2021-04-28 | — | — | EP | disclosed |
| US-10781170-B1 | Process for preparing Brivaracetam | DIVI'S LABORATORIES LTD. (IN) | 2020-09-22 | — | — | US | disclosed |
| EP-2474580-A1 | PIGMENT DISPERSION INCLUDING AZO PIGMENT AND AQUEOUS INK FOR INKJET RECORDING USING THE SAME | FUJIFILM Corporation (JP) | 2012-07-11 | — | — | EP | disclosed |
| US-20120165436-A1 | PIGMENT DISPERSION CONTAINING AZO PIGMENT AND AQUEOUS INK FOR INKJET RECORDING USING THE SAME | FUJIFILM CORPORATION (JP) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11884623-B2 | Process for the preparation of (R)-4-propyl pyrrolidine-2-one, a key intermediate for synthesis of brivaracetam | BPGM, MGAM, HPD | CRBN 2242/4885FYN 4197/4885ALDH1A1 564/4885 |
| US-10781170-B1 | Process for preparing Brivaracetam | GABRA2, GABRA1, GABRB2 | CRBN 378/4885FYN 4564/4885ALDH1A1 2638/4885 |
| US-20230373914-A1 | PROCESS FOR THE PREPARATION OF (R)-4-PROPYL PYRROLIDINE-2-ONE, A KEY INTERMEDIATE FOR SYNTHESIS OF BRIVARACETAM | BPGM, MGAM, HPD | CRBN 2242/4885FYN 4197/4885ALDH1A1 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.